glutathione mutations in sclc patients vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer Frontiers | Metabolic reprogramming in
Frontiers Metabolic reprogramming in lung cancer and its clinical implication Inhibiting the system xC glutathione axis selectively targets cancers with mutant p53 accumulation Nature Communications Promises of Protein Kinase Inhibitors in Recalcitrant Small Cell Lung Cancer: Recent Scenario and Future Possibilities Tumor suppressor genes and KRAS G12C inhibitor resistance in non small cell lung cancer: iScience
Pay in 4 interest-free payments of $6.94 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



